PMID: 8988956Jan 1, 1997Paper

Effect of pindolol in hastening response to fluoxetine in the treatment of major depression: a double-blind, placebo-controlled trial

The American Journal of Psychiatry
Robert M BermanDennis S Charney

Abstract

In two preliminary studies, pindolol produced robust results in hastening clinical response to antidepressant drugs in depressed patients. Validity of those pilot studies was limited by use of an open-label, unblinded study design, and so the authors conducted a double-blind, placebo-controlled trial to assess the effectiveness of pindolol in hastening response to fluoxetine. Drug-free outpatients with major depression were concurrently treated with fluoxetine (20 mg/day) and either placebo or pindolol (5.0 mg b.i.d. or 2.5 mg t.i.d.), for 6 weeks, in a randomized, double-blind manner. After 6 weeks, all patients received fluoxetine and placebo and were followed for 3 further weeks in a single-blind manner. Forty-three patients completed at least 1 week of the protocol. Rates of partial remission after 2 weeks of treatment with fluoxetine and either pindolol or placebo were 17% (four of 23 patients) and 20% (four of 20 patients), respectively. At study completion, 65% of the patients (N = 28) demonstrated at least a partial remission, and there was no difference between treatment groups. The pindolol group, but not the placebo group, demonstrated significant reductions in blood pressure and pulse rate. The average time to remis...Continue Reading

Citations

Jan 7, 1998·Clinical Therapeutics·P E Stokes, A Holtz
Oct 16, 1999·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·M Isaac
May 4, 2000·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·P N DannonJ Zohar
Aug 12, 1999·European Journal of Pharmacology·P Skolnick
Mar 20, 2002·Pharmacology, Biochemistry, and Behavior·Mariusz PappConnie Sánchez
Sep 8, 2010·Life Sciences·Vânia R SelaElisabeth A Audi
May 12, 2009·Progress in Neurobiology·Jonathan SavitzWayne C Drevets
Dec 7, 2007·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Christian GeretseggerWolfgang Aichhorn
Mar 17, 2007·Journal of Affective Disorders·Wendelien MerensPhilip Spinhoven
Jul 26, 1997·Lancet·M T Isaac, M B Tome
Mar 2, 2011·Neuropharmacology·Benjamin Adam SamuelsRené Hen
Apr 23, 2003·Biological Psychiatry·Lori L AltshulerMichael J Gitlin
Nov 30, 2000·Epidemiologia e psichiatria sociale·E S Paykel
Oct 31, 2002·Human Psychopharmacology·John F. Cryan, Brian E. Leonard
Mar 24, 2004·Biochemical Pharmacology·Andria L Del TrediciDavid M Weiner
Jun 1, 1997·The Australian and New Zealand Journal of Psychiatry·I SchweitzerG Johnson
Jun 24, 2004·The Australian and New Zealand Journal of Psychiatry·Peter Ellis, UNKNOWN Royal Australian and New Zealand College of Psychiatrists Clinical Practice Guidelines Team for Depression
Oct 31, 2002·Human Psychopharmacology·Frederick E. Miller
Jan 1, 1998·International Journal of Psychiatry in Clinical Practice·J S Olver, G D Burrows
Jul 13, 2000·Journal of Psychopharmacology·S HjorthS B Auerbach
Mar 7, 2003·Cardiology in Review·Seth Keller, William H Frishman
Oct 16, 2004·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Carolyn Cidis MeltzerCharles F Reynolds
Feb 24, 2001·The Australian and New Zealand Journal of Psychiatry·J S OlverT R Norman

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.